As per the research report, the size of the Europe Microbiome sequencing services market size is valued at USD 254.03 Million in 2021. It is expected to grow at a CAGR of 21.17% to reach USD 663.54 Million by 2026 during the forecast period 2021 to 2026.
Microbiome sequencing is the analysis of microbial groups located in and on the human body. The objective of human microbiome research is to comprehend the function of microbes in health and disease. Conventionally, examining samples from human skin, stool, or blood was dependent on time and labor-intensive microbiology procedures of growing and isolating individual organisms followed by phenotypic or genotypic analysis. However, the arrival of next-generation sequencing (NGS) has enabled numerous high-profile collaborative projects, which have published an extensive range of data on the human microbiome utilizing NGS as a foundational tool.
The main factors fuelling the market development are the rising utilization of microbiomes in genomics, proteomics, and metabolomics and mechanical headways in cutting edge sequencing. Then again, the absence of adequate regulations, government directions, and moral and legitimate issues identified with NGS are the main considerations limiting the development of the microbiome sequencing services market.
This research report segmented and sub-segmented into the following categories:
In Europe, the market is concentrated in the UK and Germany. The market is expected to witness major growth owing to the presence of key players and increasing awareness towards NGS.
Key players operating in the Europe Microbiome sequencing services market profiled in this report are Metabiomics Corp., Microbiome Therapeutics LLC, Microbiome Insights Inc., Rancho Biosciences, Zymo Research Corp., Molzym GmbH & Co., Ubiome Inc., Diversigen Inc., Merieux Nutrisciences Corporation, and Molecular Research LP.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Technology
5.1.1 Introduction
5.1.2 sequencing by synthesis
5.1.3 sequencing by ligation
5.1.4 pyrosequencing
5.1.5 sanger sequencing
5.1.6 Other technologies
5.1.7 Y-o-Y Growth Analysis, By Technology
5.1.8 Market Attractiveness Analysis, By Technology
5.1.9 Market Share Analysis, By Technology
5.2 Application
5.2.1 Introduction
5.2.2 shotgun sequencing
5.2.3 targeted gene sequencing
5.2.4 RNA sequencing
5.2.5 whole genome sequencing
5.2.6 Other applications
5.2.7 Y-o-Y Growth Analysis, By Application
5.2.8 Market Attractiveness Analysis, By Application
5.2.9 Market Share Analysis, By Application
5.3 Research type
5.3.1 Introduction
5.3.2 Internal research
5.3.3 Outsourced researchDrug
5.3.4 Y-o-Y Growth Analysis, By research type
5.3.5 Market Attractiveness Analysis, By research type
5.3.6 Market Share Analysis, By research type
5.4 Laboratory type
5.4.1 Introduction
5.4.2 Wet lab
5.4.3 Dry lab
5.4.4 Y-o-Y Growth Analysis, By Laboratory type
5.4.5 Market Attractiveness Analysis, By Laboratory type
5.4.6 Market Share Analysis, By Laboratory type
5.5 End user
5.5.1 Introduction
5.5.2 Pharmaceutical
5.5.3 Biotechnology
5.5.4 Y-o-Y Growth Analysis, By End user
5.5.5 Market Attractiveness Analysis, By End user
5.5.6 Market Share Analysis, By End user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Technology
6.1.3.3 By Application
6.1.3.4 By Research type
6.1.3.5 By laboratory type
6.1.3.6 By End user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Technology
6.1.4.3 By Application
6.1.4.4 By Research type
6.1.4.5 By laboratory type
6.1.4.6 By End user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Technology
6.1.5.3 By Application
6.1.5.4 By Research type
6.1.5.5 By laboratory type
6.1.5.6 By End user
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Metabiomics Corp
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Microbiome Therapeutics LLC
8.3 Microbiome Insights Inc.
8.4 Rancho Biosciences
8.5 Zymo Research Corp
8.6 Molzym GmbH & Co.
8.7 Celgene Corporation
8.8 Ubiome Inc.
8.9 Diversigen Inc.
8.10 Merieux Nutrisciences Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
